Targeting STAT3 and STAT5 in Cancer
Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur...
Saved in:
| HerausgeberIn: | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (578 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993545845904498 |
|---|---|
| ctrlnum |
(CKB)5400000000045180 (oapen)https://directory.doabooks.org/handle/20.500.12854/69075 (EXLCZ)995400000000045180 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Targeting STAT3 and STAT5 in Cancer Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (578 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur in a critical cellular signaling pathway, the JAK-STAT pathway; (Janus Kinase-Signal Transducer and Activator of Transcription). Currently, there are no clinically available drugs that target the oncogenic STAT3/5 proteins in particular or their Gain of Function hyperactive mutant products. Here, we summarize targeting approaches on STAT3/5, as the field moves towards clinical applications as well as we illuminate on upstream or downstream JAK-STAT pathway interference with kinase inhibitors, heat shock protein blockers or changing nuclear import/export processes. We cover the design paradigms and medicinal chemistry approaches to illuminate progress and challenges in understanding the pleiotropic role of STAT3 and STAT5 in oncogenesis, the microenvironment, the immune system in particular, all culminating in a complex interplay towards cancer progression. English Research & information: general bicssc Biology, life sciences bicssc multiple myeloma STAT3 S3I-1757 nanoparticle CD38 siRNA/RNAi polyethylenimine PEI lipopolyplex siRNA delivery glioma glioblastoma STAT5 AKT ERK1/2 prolactin androgens prostate cancer knockout escape mechanisms stem/progenitor cells cell hierarchy cancer CD4+ T cells CD8+ T cells myeloid cells immune check point hepatitis C virus (HCV) cirrhosis hepatocellular carcinoma (HCC) endoplasmic reticulum (ER) stress oxidative stress (OS) unfolded protein response (UPR) microRNA-122 (miR-122) nuclear factor erythroid 2-related factor 2 (NRF2) signal transducer and activator of transcription 3 (STAT3) hepatocyte nuclear factor 4 alpha (HNF4A) solid cancers cell cycle apoptosis inflammation mitochondria stemness tumor suppression melanoma autoimmune disease immunotherapy tumor-immune cell interactions breast cancer PD-L1 M2 macrophages NK cells STAT3 inhibitor XIII hedging transaction costs dynamic programming risk management post-decision state variable cancer progression cancer-stem cell cytokine therapy resistance metastasis immunosuppression tumor microenvironment proliferation tyrosine kinase 2 JAK family of protein tyrosine kinases signal transducer and activator of transcription cytokine receptor signaling gain-of-function mutation tumorigenesis ADAM17 interleukin-6 trans-signaling epidermal growth factor receptor (EGF-R) shedding metalloprotease tumor necrosis factor alpha (TNFα) inflammation associated cancer colon cancer lung cancer SH2 domain mutations autosomal-dominant hyper IgE syndrome inflammatory hepatocellular adenomas T-cell large granular lymphocytic leukemia T-cell prolymphocytic leukemia growth hormone insensitivity syndrome nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling targeting tumor-associated macrophages adoptive T cell therapy immune suppression STAT transcription factors JAK STAT T-PLL T-cell leukemia meta-analysis STAT5B signaling small-molecule inhibitors cancer models companion animals comparative oncology pharmacological inhibitor STAT5 signaling chemotherapy resistance myeloid leukemia heat shock proteins chaperones stabilization targeted therapy ovarian cancer hematopoietic cancers therapeutic targeting pharmacological inhibitors mTOR Bone Marrow Failure Syndromes lymphocytes lymphoma T-cells RHOA NGS MPN JAK2 V617F neoplastic stem cells 3-03943-036-X 3-03943-037-8 Gunning, Patrick edt Keserü, G. M. edt Moriggl, Richard edt |
| language |
English |
| format |
eBook |
| author2 |
Gunning, Patrick Keserü, G. M. Moriggl, Richard |
| author_facet |
Gunning, Patrick Keserü, G. M. Moriggl, Richard |
| author2_variant |
p g pg g m k gm gmk r m rm |
| author2_role |
HerausgeberIn HerausgeberIn HerausgeberIn |
| title |
Targeting STAT3 and STAT5 in Cancer |
| spellingShingle |
Targeting STAT3 and STAT5 in Cancer |
| title_full |
Targeting STAT3 and STAT5 in Cancer |
| title_fullStr |
Targeting STAT3 and STAT5 in Cancer |
| title_full_unstemmed |
Targeting STAT3 and STAT5 in Cancer |
| title_auth |
Targeting STAT3 and STAT5 in Cancer |
| title_new |
Targeting STAT3 and STAT5 in Cancer |
| title_sort |
targeting stat3 and stat5 in cancer |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2020 |
| physical |
1 electronic resource (578 p.) |
| isbn |
3-03943-036-X 3-03943-037-8 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT gunningpatrick targetingstat3andstat5incancer AT keserugm targetingstat3andstat5incancer AT morigglrichard targetingstat3andstat5incancer |
| status_str |
n |
| ids_txt_mv |
(CKB)5400000000045180 (oapen)https://directory.doabooks.org/handle/20.500.12854/69075 (EXLCZ)995400000000045180 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Targeting STAT3 and STAT5 in Cancer |
| author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
| _version_ |
1798147204746051584 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06570nam-a2201861z--4500</leader><controlfield tag="001">993545845904498</controlfield><controlfield tag="005">20240503233455.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045180</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69075</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045180</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Targeting STAT3 and STAT5 in Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (578 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur in a critical cellular signaling pathway, the JAK-STAT pathway; (Janus Kinase-Signal Transducer and Activator of Transcription). Currently, there are no clinically available drugs that target the oncogenic STAT3/5 proteins in particular or their Gain of Function hyperactive mutant products. Here, we summarize targeting approaches on STAT3/5, as the field moves towards clinical applications as well as we illuminate on upstream or downstream JAK-STAT pathway interference with kinase inhibitors, heat shock protein blockers or changing nuclear import/export processes. We cover the design paradigms and medicinal chemistry approaches to illuminate progress and challenges in understanding the pleiotropic role of STAT3 and STAT5 in oncogenesis, the microenvironment, the immune system in particular, all culminating in a complex interplay towards cancer progression.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biology, life sciences</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multiple myeloma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">S3I-1757</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD38</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">siRNA/RNAi</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polyethylenimine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PEI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipopolyplex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">siRNA delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AKT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ERK1/2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prolactin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgens</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">knockout</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">escape mechanisms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stem/progenitor cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell hierarchy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD4+ T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD8+ T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">myeloid cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune check point</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatitis C virus (HCV)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cirrhosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatocellular carcinoma (HCC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">endoplasmic reticulum (ER) stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative stress (OS)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">unfolded protein response (UPR)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA-122 (miR-122)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nuclear factor erythroid 2-related factor 2 (NRF2)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">signal transducer and activator of transcription 3 (STAT3)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatocyte nuclear factor 4 alpha (HNF4A)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solid cancers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell cycle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mitochondria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stemness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor suppression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autoimmune disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor-immune cell interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">M2 macrophages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NK cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT3 inhibitor XIII</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hedging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transaction costs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dynamic programming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk management</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">post-decision state variable</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer progression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer-stem cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunosuppression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proliferation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase 2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">JAK family of protein tyrosine kinases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">signal transducer and activator of transcription</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokine receptor signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gain-of-function mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumorigenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADAM17</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interleukin-6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">trans-signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epidermal growth factor receptor (EGF-R)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">shedding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metalloprotease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor necrosis factor alpha (TNFα)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation associated cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colon cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SH2 domain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autosomal-dominant hyper IgE syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammatory hepatocellular adenomas</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-cell large granular lymphocytic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-cell prolymphocytic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">growth hormone insensitivity syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nuclear pore complex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nuclear transport receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nucleocytoplasmic shuttling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor-associated macrophages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adoptive T cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune suppression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT transcription factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">JAK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-PLL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-cell leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT5B signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">small-molecule inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer models</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">companion animals</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comparative oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacological inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STAT5 signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">myeloid leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heat shock proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chaperones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stabilization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hematopoietic cancers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacological inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bone Marrow Failure Syndromes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lymphocytes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lymphoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RHOA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NGS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MPN</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">JAK2 V617F</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neoplastic stem cells</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-036-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-037-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunning, Patrick</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Keserü, G. M.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moriggl, Richard</subfield><subfield code="4">edt</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-05-04 08:43:48 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338106320004498&Force_direct=true</subfield><subfield code="Z">5338106320004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338106320004498</subfield></datafield></record></collection> |